Difference between revisions of "Tyrosine kinase inhibitors"
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
Others - used in [[RCC]]:<ref>URL: [http://dtb.bmj.com/content/49/11/129.abstract http://dtb.bmj.com/content/49/11/129.abstract]. Accessed on: 3 October 2014</ref> | Others - used in [[RCC]]:<ref>URL: [http://dtb.bmj.com/content/49/11/129.abstract http://dtb.bmj.com/content/49/11/129.abstract]. Accessed on: 3 October 2014</ref> | ||
* Sunitinib (Sutent). | * [[Sunitinib]] (Sutent). | ||
* Sorafenib (Nexavar). | * Sorafenib (Nexavar). | ||
* Pazopanib (Votrient). | * Pazopanib (Votrient). | ||
Revision as of 15:06, 20 October 2014
Tyrosine kinase inhibitors, abbreviated TKIs, are a group of drugs that inhibit the action of tyrosine kinases.
The category includes many cancer drugs - including:
- Imatinib (Gleevec).
- Gefitinib (Iressa).
- Erlotinib (Tarceva).
- Sunitinib (Sutent).
- Sorafenib (Nexavar).
- Pazopanib (Votrient).
Use
See also
References
- ↑ URL: http://dtb.bmj.com/content/49/11/129.abstract. Accessed on: 3 October 2014
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.